Navigation Links
Using millions of years of cell evolution in the fight against cancer
Date:8/7/2012

As the medical community continues to make positive strides in personalized cancer therapy, scientists know some dead ends are unavoidable. Drugs that target specific genes in cancerous cells are effective, but not all proteins are targetable. In fact, it has been estimated that as few as 10 to 15 percent of human proteins are potentially targetable by drugs. For this reason, Georgia Tech researchers are focusing on ways to fight cancer by attacking defective genes before they are able to make proteins.

Professor John McDonald is studying micro RNAs (miRNAs), a class of small RNAs that interact with messenger RNAs (mRNAs) that have been linked to a number of diseases, including cancer. McDonald's lab placed two different miRNAs (MiR-7 and MiR-128) into ovarian cancer cells and watched how they affected the gene system. The findings are published in the current edition of the journal BMC Medical Genomics.

"Each inserted miRNA created hundreds of thousands of gene expression changes, but only about 20 percent of them were caused by direct interactions with mRNAs," said McDonald. "The majority of the changes were indirect they occurred downstream and were consequences of the initial reactions."

McDonald initially wondered if those secondary interactions could be a setback for the potential use of miRNAs, because most of them changed the gene expressions of something other than the intended targets. However, McDonald noticed that most of what changed downstream was functionally coordinated.

miR-7 transfection most significantly affected the pathways involved with cell adhesion, epithelial-mesenchymal transitions (EMT) and other processes linked with cancer metastasis. The pathways most often affected by miR-128 transfection were different. They were more related to cell cycle control and processes involved with cellular replication another process that is overactive in cancer cells.

"miRNAs have evolved for millions of years in order to coordinately regulate hundreds to thousands of genes together on the cellular level," said McDonald. "If we can understand which miRNAs affect which suites of genes and their coordinated functions, it could allow clinicians to attack cancer cells on a systems level, rather than going after genes individually."

Clinical trials for miRNAs are just beginning to be explored, but definitive findings are likely still years away because there are hundreds of miRNAs whose cellular functions must be fully understood. Another challenge facing scientists is developing ways to effectively target therapeutic miRNAs to cancer cells, something McDonald and his Georgia Tech peers are also investigating.


'/>"/>
Contact: Jason Maderer
maderer@gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert

Related biology news :

1. Frequent traveller: Dysentery-causing bacteria spreading from Europe to Australia
2. Using wastewater as fertilizer
3. 3-D motion of cold virus offers hope for improved drugs using Australias fastest supercomputer
4. Real-life spider men using protein found in venom to develop muscular dystrophy treatment
5. Silver nanoparticle synthesis using strawberry tree leaf
6. Bangladeshi women prefer pollution-causing cookstoves
7. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
8. Using graphene, scientists develop a less toxic way to rust-proof steel
9. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
10. Better housing conditions for zebrafish could improve research results
11. What is really causing the child obesity epidemic?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology: